Targeting METTL3 using the specific inhibitor STM2457 improves the sensitivity to lenvatinib in vitro and in vivo, indicating that METTL3 may be a potential therapeutic target to overcome lenvatinib resistance in HCC (Wang et al., 2023c). This evidence concerns the gene METTL3 and hepatocellular carcinoma.